logo-loader

Todos trademarks Tollovid for dietary supplement NLC-001 and strikes distribution deal with The Alchemists Kitchen

Published: 14:20 29 Oct 2020 GMT

Todos Medical Ltd. - Todos trademarks Tollovid for dietary supplement NLC-001 and strikes distribution deal with The Alchemists Kitchen
Alchemist’s Kitchen CEO Lou Sagar said Tollovid certainly is a unique asset in the botanical wellness space and include a 3CL protease inhibitor that could help support immunity

Todos Medical Ltd (OTCQB:TOMDF) announced on Thursday that it has selected the brand name Tollovid for its patented dietary supplement NLC-001, which is a blend of plant extracts that include a 3CL protease inhibitor that could help support strong immunity.

Rehovot, Israel-based Todos Medical noted that 3CL protease plays “a vital role” in the intracellular replication of coronaviruses, and 3CL protease inhibition is being evaluated as a potential therapeutic target for COVID-19 by several groups, including Pfizer Inc (NYSE:PFE).

In September, Todos licensed the exclusive worldwide distribution rights (excluding Israel) for Tollovid from its joint venture partner NLC Pharma.

READ: Todos Medical announces completion of instrument validation in its mobile lab division

Concurrently, Todos revealed it has struck a private label and distribution agreement with The Alchemist’s Kitchen, in SoHo, in New York to sell Tollovid under its Plant Alchemy brand. The New-York-based company will train its herbalists to “educate consumers on how adding Tollovid to their immune-boosting strategy could potentially lead to improved outcomes in the face of circulating coronaviruses.”

The Alchemist’s Kitchen has a significant online presence has been featured in several high-profile educational series, including Dr Sanjay Gupta’s CBD and cannabis specials on CNN.

“Tollovid certainly is a unique asset in the botanical wellness space, and we are very pleased to be the first to bring this product to market in the United States,” said The Alchemist’s Kitchen CEO Lou Sagar in a statement.

“It’s clear there has been a tremendous amount of science developed around Tollovid as it relates to 3CL inhibition, and we believe this could be an important mechanism during this critical time heading into the colder months of the year where people will congregate indoors more often.”

Sagar noted that The Alchemist’s Kitchen is always looking to be on “the cutting edge of innovation in the botanical wellness space,” and Tollovid certainly “reinforces our market-leading position.”

“We are excited to have selected the brand name Tollovid for NLC-001 and to be partnering with The Alchemist’s Kitchen to bring this important immune-boosting dietary supplement into the marketplace at this critical time in the United States,” said Todos Medical CEO Gerald E Commissiong.

“Some of the most promising data in the scientific literature to date in combatting coronaviruses has been generated by dietary supplements that help reinforce the body’s ability to respond to potential challenges from a coronavirus infection … We believe Tollovid could be an important part of an immune-boosting strategy.”

Todos Medical develops diagnostic solutions to screen for a variety of cancers and neurodegenerative disorders, but it has recently pivoted to the coronavirus (COVID-19) PCR testing space and won a string of high-value contracts.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

New capital allocation framework positions Ecora firmly for Energy...

  Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) CEO Marc Bishop Lafleche discusses the company's transition away from its Kestrel royalty and its impact on the company's 2023 financials, highlighting periods of variable mining activity within the orchestral royalty area. In an...

1 day, 4 hours ago